Laboratory of Age-related Metabolic Endocrine Disorders of Pirogov Russian National Research Medical University of Ministry of Health of Russian Federation "Russian Gerontology Research and Clinical Centre", Moscow, Russia.
National Medical Research Centre for Therapy and Preventive Medicine, Moscow, Russia.
Cardiovasc Drugs Ther. 2022 Dec;36(6):1147-1155. doi: 10.1007/s10557-021-07235-6. Epub 2021 Sep 15.
To compare the effect of 12 months of treatment with moxonidine or bisoprolol on telomerase activity (TA) and parameters characterizing the arterial wall state in postmenopausal women with arterial hypertension (AH) and osteopenia.
An open-label randomized study with 114 postmenopausal women with hypertension and osteopenia; pulse wave velocity (PWV), intima-media thickness (IMT), and TA were analyzed initially and after 12 months of therapy with moxonidine (n = 57) or bisoprolol (n = 57).
Both medications effectively lowered blood pressure (BP) in both groups. After 12 months, the moxonidine group showed a significant increase in TA by 45.5% (from 0.87 to 1.15; p < 0.001), in contrast to the bisoprolol group, where TA decreased by 14.1% (from 0.89 to 0.74; p = 0.001). Within 12 months, in the moxonidine group, PWV decreased by 1.9% (from 10.35 ± 2.56 to 10.05 ± 2.29 m/s; p = 0.039), and in the bisoprolol group it increased by 5.8% (from 10.36 ± 2.47 to 11.26 ± 2.60 m/s; p < 0.001). In the moxonidine group, IMT increased by 3.5% on the right and 1.4% on the left, in the bisoprolol group - by 5.7% on the right and 4.2% on the left.
A 12-month treatment with moxonidine but not with bisoprolol in postmenopausal women with AH and osteoporosis was associated with a decrease of arterial stiffness seen as statistically significantly reduced PVW and with increased TA.
比较莫索尼定和比索洛尔治疗 12 个月对绝经后女性动脉高血压(AH)和骨质疏松症患者端粒酶活性(TA)和动脉壁状态参数的影响。
这是一项开放标签、随机研究,纳入了 114 名绝经后高血压合并骨质疏松症患者;最初和治疗 12 个月后,分析脉搏波速度(PWV)、内膜中层厚度(IMT)和 TA,这些患者分别接受莫索尼定(n = 57)或比索洛尔(n = 57)治疗。
两种药物均能有效降低两组患者的血压(BP)。12 个月后,莫索尼定组 TA 显著升高 45.5%(从 0.87 升至 1.15;p < 0.001),而比索洛尔组 TA 降低 14.1%(从 0.89 降至 0.74;p = 0.001)。在 12 个月内,莫索尼定组 PWV 降低 1.9%(从 10.35 ± 2.56 降至 10.05 ± 2.29 m/s;p = 0.039),而比索洛尔组增加 5.8%(从 10.36 ± 2.47 增至 11.26 ± 2.60 m/s;p < 0.001)。莫索尼定组右侧 IMT 增加 3.5%,左侧增加 1.4%,比索洛尔组右侧增加 5.7%,左侧增加 4.2%。
在绝经后 AH 和骨质疏松症女性中,12 个月的莫索尼定治疗而不是比索洛尔治疗与动脉僵硬度降低有关,表现为 PWV 统计学显著降低,TA 增加。